Literature DB >> 22125177

Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.

William Breuer1, Hussam Ghoti, Ahmmad Shattat, Ada Goldfarb, Ariel Koren, Carina Levin, Eliezer Rachmilewitz, Z Ioav Cabantchik.   

Abstract

Non-transferrin bound iron (NTBI) is commonly detected in patients with systemic iron overload whose serum iron-binding capacity has been surpassed. It has been perceived as an indicator of iron overload, impending organ damage and a chelation target in poly-transfused thalassemia patients. However, NTBI is a heterogeneous entity comprising various iron complexes, including a significant redox-active and readily chelatable fraction, which we have designated as "labile plasma iron" (LPI). We found that LPI levels can be affected by plasma components such as citrate, uric acid, and albumin. However, the inclusion of a mild metal mobilizing agent in the LPI assay (designated here as "eLPI"), at concentrations that do not affect transferrin-bound iron, largely overcomes such effects and provides a measure of the full NTBI content. We analyzed three distinct groups of poly-transfused, iron overloaded thalassemia patients: non-chelated children (3-13 yrs, Gaza, Palestine), chelated adolescents-young adults (13-28 yrs, Israel), and chelated adults (27-61 yrs, Israel) for LPI and eLPI. The eLPI levels in all three groups were roughly commensurate (r(2) = 0.61-0.75) with deferrioxamine-detectable NTBI, i.e., DCI. In older chelated patients, eLPI levels approximated those of LPI, but in poly-transfused unchelated children eLPI was notably higher than LPI, a difference attributed to plasma properties affected by labile iron due to lack of chelation, possibly reflecting age-dependent attrition of plasma components. We propose that the two formats of NTBI measurement presented here are complementary and used together could provide more comprehensive information on the forms of NTBI in patients and their response to chelation.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22125177     DOI: 10.1002/ajh.22203

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Authors:  Louise de Swart; Jan C M Hendriks; Lisa N van der Vorm; Z Ioav Cabantchik; Patricia J Evans; Eldad A Hod; Gary M Brittenham; Yael Furman; Boguslaw Wojczyk; Mirian C H Janssen; John B Porter; Vera E J M Mattijssen; Bart J Biemond; Marius A MacKenzie; Raffaella Origa; Renzo Galanello; Robert C Hider; Dorine W Swinkels
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941

2.  A decisional algorithm to start iron chelation in patients with beta thalassemia.

Authors:  Fabrice Danjou; Zvi Ioav Cabantchik; Raffaella Origa; Paolo Moi; Michela Marcias; Susanna Barella; Elisabetta Defraia; Carlo Dessì; Maria Loreta Foschini; Nicolina Giagu; Giovan Battista Leoni; Maddalena Morittu; Renzo Galanello
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

3.  The role of endocytic pathways in cellular uptake of plasma non-transferrin iron.

Authors:  Yang-Sung Sohn; Hussam Ghoti; William Breuer; Eliezer Rachmilewitz; Samah Attar; Guenter Weiss; Z Ioav Cabantchik
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

4.  Brain iron metabolism and brain injury following subarachnoid hemorrhage: iCeFISH-pilot (CSF iron in SAH).

Authors:  Joao A Gomes; Magdy Selim; Anne Cotleur; M Shazam Hussain; Gabor Toth; Lauren Koffman; Khaled Asi; J Javier Provencio
Journal:  Neurocrit Care       Date:  2014-10       Impact factor: 3.210

5.  Mössbauer study and modeling of iron import and trafficking in human jurkat cells.

Authors:  Nema D Jhurry; Mrinmoy Chakrabarti; Sean P McCormick; Vishal M Gohil; Paul A Lindahl
Journal:  Biochemistry       Date:  2013-11-01       Impact factor: 3.162

6.  Iron metabolism in hemodialyzed patients - a story half told?

Authors:  Jolanta Malyszko; Ewa Koc-Zorawska; Nomy Levin-Iaina; Itzchak Slotki; Joanna Matuszkiewicz-Rowinska; Irena Glowinska; Jacek S Malyszko
Journal:  Arch Med Sci       Date:  2014-12-22       Impact factor: 3.318

7.  Effects of therapeutic zinc supplementation for diarrhea and two preventive zinc supplementation regimens on the incidence and duration of diarrhea and acute respiratory tract infections in rural Laotian children: A randomized controlled trial.

Authors:  Maxwell A Barffour; Guy-Marino Hinnouho; K Ryan Wessells; Sengchanh Kounnavong; Kethmany Ratsavong; Dalaphone Sitthideth; Bangone Bounheuang; Khanpaseuth Sengnam; Bigphone Chanhthavong; Charles D Arnold; Kenneth H Brown; Charles P Larson; Sonja Y Hess
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

8.  Extracellular Vesicle Characteristics in β-thalassemia as Potential Biomarkers for Spleen Functional Status and Ineffective Erythropoiesis.

Authors:  Carina Levin; Ariel Koren; Annie Rebibo-Sabbah; Naama Koifman; Benjamin Brenner; Anat Aharon
Journal:  Front Physiol       Date:  2018-08-30       Impact factor: 4.566

9.  Treating thalassemia major-related iron overload: the role of deferiprone.

Authors:  Vasilios Berdoukas; Kallistheni Farmaki; Susan Carson; John Wood; Thomas Coates
Journal:  J Blood Med       Date:  2012-10-19

Review 10.  Labile iron in cells and body fluids: physiology, pathology, and pharmacology.

Authors:  Zvi Ioav Cabantchik
Journal:  Front Pharmacol       Date:  2014-03-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.